M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical TechnologyEli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Technology Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
